Featured on: United Press International
Publication date: Apr 9, 2009
Publication date: Apr 9, 2009
In response to the risk of patients developing the potentially fatal neurological disease progressive multifocal leukoencephalopathy (PML), Genetech Inc. has taken the decision to remove the psoriasis drug Raptiva from the U.S. market. Doctors are advised to discuss alternative therapies with patients. The FDA says that prescribers should not initiate new Raptiva treatment.
Read Full Article
Read Full Article
More Skin Articles
Natural Solutions For Diaper Rash & EczemaTeens & Tanning Safely
Largest Survey Of Its Kind Finds That People With Psoriasis Are At Risk For Other Medical Conditi
Experts Recommend Moisturizers With Lactic Acid To Manage Their Dry Skin Associated With Keratosi
Diary Of A Homeophobe: Part One
Psoriasis: A Patchy Affair
Hope For 14 Million+ Rosacea Sufferers
Synthesizing The Most Natural Of All Skin Creams
Iron-Binding Drug Could Help Diabetics Heal Stubborn Wounds
Infection Insidious, As In Case Of Rower
